Yükleniyor... / Loading...
This study evaluates Galinpepimut-S (a vaccine targeting the WT-1 protein) in patients with malignant pleural mesothelioma (a cancer of the lung lining) after combined-modality therapy (surgery, chemotherapy, and/or radiation). It included patients with confirmed disease whose tumors express the WT-1 protein. It was a Phase 2 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Pathologic diagnosis of malignant pleural mesothelioma (MPM) confirmed at participating institution. * Positive immunohistochemical staining for WT-1 (greater than 10% of cells). * Completion of multimodality therapy. This must include surgical resection by either pleurectomy/decortication or extrapleural pneumonectomy. The surgery should be performed with the intent of complete resection, though patients with an R1 resection will still be eligible. Patients should have also received treatment with chemotherapy and/or radiation. Patients with an R2 resection are also eligible as long as the site of residual disease is treated post-operatively with radiotherapy. * 4-12 weeks since completion of combined modality therapy. * Age \> or = to 18 years * Karnofsky performance status \> or = to 70% * Hematologic parameters: Absolute neutrophil count \> or = to 1000/mcL, Platelets \> or = to 50K/mcL. * Biochemical parameters: Total bilirubin \< or = to 2.0 mg/dl, AST and ALT \< or = to 2.5 x upper limits of normal, Creatinine \< or = to 2.0 mg/dl. Exclusion Criteria: * Pregnant or lactating women. * Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments. * Patients with a serious unstable medical illness or another active cancer. * Patients taking systemic corticosteroids. * Patients with an immunodeficiency syndrome.